The Human Genome Sequencing Center at Baylor College of Medicine plans to use Roche NimbleGen exome capture products as part of an effort to sequence more than 5,000 human exomes over the next two years to discover genetic variants underlying a number of human diseases, the company said this week.
Funded by the National Institutes of Health and several research consortia, Baylor researchers plan to study more than 15 diseases by exome sequencing, including cancer of the brain, liver, pancreas, colon, ovary, and bladder; heart disease; diabetes; autism; and several inherited diseases.
The center will use both NimbleGen's SeqCap EZ Exome and customized NimbleGen exome designs in these studies, according to the company. In collaboration with Roche NimbleGen, it has established a pipeline for high-throughput exome capture and sequencing “with multiple next-generation sequencing platforms.”
Baylor has already sequenced the exomes of approximately 1,000 samples, and captured and sequenced DNA from about 1,000 additional samples, according to NimbleGen.